Neticonazole hydrochloride

Neticonazole Hydrochloride (CAS No. 130773-02-3) is an imidazole compound with dual core biological activities: antifungal and antitumor effects. Its targets include pathways related to fungal cell membrane synthesis (against superficial fungi such as cutaneous Candida) and exosome secretion pathways (against colorectal cancer). Meanwhile, it can induce tumor cell apoptosis by regulating the ratio of apoptosis-related proteins Bcl-2/Bax. Regarding commonly used application concentrations, in animal experiments, the oral dosage for colorectal cancer xenograft models is 1–100 ng/kg (the optimal effective dosage is 1 ng/kg), and it is used in vitro for exosome inhibition and antifungal-related research. The clinically effective therapeutic concentrations correspond to multi-scenario applications: topical formulations (ointment, cream, lotion) are used for cutaneous candidiasis (such as intertrigo, interdigital erosion, etc.), applied once daily, with visible effects within 1–2 weeks, making it a first-line topical drug for superficial mycoses. No clinical effective dosage has been established in the antitumor field. Referring to the animal experimental dosage of 1 ng/kg orally daily, it can inhibit the occurrence and development of colorectal cancer induced by intestinal dysbacteriosis, improve the survival period of tumor-bearing animals, and has potential for colorectal cancer treatment.

References:

[1] Shono M. Allergic contact dermatitis from neticonazole hydrochloride. Contact Dermatitis. 1997 Sep;37(3):136-7. doi: 10.1111/j.1600-0536.1997.tb00328.x. PMID: 9330830.

[2] Katoh T. [Guidelines for diagnosis and treatment of mucocutaneous candidiasis]. Nihon Ishinkin Gakkai Zasshi. 2009;50(4):207-12. Japanese. doi: 10.3314/jjmm.50.207. PMID: 19942790.

[3] Gu L, Xu Y, Xu W, Li M, Su H, Li C, Liu Z. The exosome secretion inhibitor neticonazole suppresses intestinal dysbacteriosis-induced tumorigenesis of colorectal cancer. Invest New Drugs. 2020 Apr;38(2):221-228. doi: 10.1007/s10637-019-00759-7. Epub 2019 Mar 19. PMID: 30887254.